April 13th 2023
Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, share their expert perspectives on how the GVHD treatment landscape is evolving.
Drs Yi-Bin Chen and Sophie Paczesny highlight data from key investigational approaches presented at recent meetings.
Yi-Bin Chen, MD, reviews the treatment options for patients with steroid-refractory chronic GVHD.
Drs Paczesny and Chen explain the importance of treating chronic GVHD as early as possible, and whether steroids are still the standard first-line treatment.
April 6th 2023
Sophie Paczesny, MD, PhD, and Yi-Bin Chen, MD, detail novel strategies under investigation for the treatment of acute GVHD.
Experts discuss the current options for treating acute GVHD, including the use of corticosteroids and their management.
March 31st 2023
Drs Yi-Bin Chen and Sophie Paczesny review the diagnosis and staging of both acute and chronic GVHD, and the challenges clinicians may encounter.
Yi-Bin Chen, MD, shares the most common GVHD prophylaxis regimens, and which regimen he typically chooses for his patients with GVHD.
March 23rd 2023
Dr Sophie Paczesny details the incidence of graft versus host disease (GVHD) in patients receiving allogeneic transplants, and Dr Yi-Bin Chen describes the differing risk factors for acute and chronic GVHD.
Sophie Paczesny, MD, PhD, explains which malignancies allogeneic transplantation can be used as a potentially curative treatment approach, and which patients are best suited for transplant.
February 22nd 2022
Drs Sophie Paczesny, Hannah Choe, Nelson J. Chao, and Yi-Bin Chen share unmet needs in GVHD and advice for disease management.
Hannah Choe, MD, leads a review of the role of supportive care and a multidisciplinary team approach to care for the treatment of steroid-refractory chronic GVHD.
Drs Hannah Choe, Nelson J. Chao, Sophie Paczesny, and Yi-Bin Chen share their approach to treating patients with chronic GVHD who present initially with either scleroderma or bronchiolitis obliterans.
February 15th 2022
Drs Hannah Choe, Yi-Bin Chen, Nelson J. Chao, and Sophie Paczesny explore emerging treatment options in the pipeline for the treatment of steroid-refractory chronic GVHD.
Hannah Choe, MD, leads the discussion on clinical experiences using off-label regimens to treat steroid-refractory chronic GVHD, and the optimal sequencing of therapy.
February 8th 2022
Hannah Choe, MD; Sophie Paczesny, MD, PhD; and Nelson J. Chao, MD, MBA, review the use of current FDA approved therapies—ruxolitinib, ibrutinib, and belumosudil—for the treatment of steroid-refractory chronic GVHD.
Yi-Bin Chen, MD, leads a discussion on the use of steroids as first-line treatment of chronic GVHD and when to switch therapy.
February 1st 2022
Nelson J. Chao, MD, MBA, and Hannah Choe, MD, define steroid-refractory acute GVHD and current treatment options for the disease.
Sophie Paczesny, MD, PhD, provides insight on how strategies to treat acute GVHD have changed over time regarding outcomes and pathophysiology of disease.
January 25th 2022
Hannah Choe, MD, discusses triggers to initiate acute GVHD therapy and goals of treatment.